Upstream Bio

Upstream Bio (UPB) presented data at the European Respiratory Society Congress showcasing verekitug’s mechanism of action. Verekitug prevents TSLP binding by occupying receptor sites and outcompetes TSLP even with preformed receptor complexes. This supports its potential for treating TSLP-driven respiratory diseases. Phase 2 data in CRSwNP showed significant improvements. A Phase 2 readout in severe asthma is expected in Q1 2026. Verekitug’s high affinity and inhibition of the TSLP receptor could lead to less frequent dosing than current therapies.

Upstream Bio (UPB) will announce Phase 2 VIBRANT trial top-line data for verekitug in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) on September 2, 2025. The global, placebo-controlled study evaluated verekitug, a monoclonal antibody targeting TSLP, administering 100 mg subcutaneously every 12 weeks. The primary endpoint is the change in endoscopic nasal polyp score (NPS) at Week 24. A conference call and webcast will be held at 8:00 a.m. ET to discuss the results. Verekitug is unique for targeting TSLP, a key driver of inflammatory responses.